Andrés López

825 total citations
28 papers, 410 citations indexed

About

Andrés López is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Andrés López has authored 28 papers receiving a total of 410 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 16 papers in Oncology and 13 papers in Genetics. Recurrent topics in Andrés López's work include Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Viral-associated cancers and disorders (7 papers). Andrés López is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Viral-associated cancers and disorders (7 papers). Andrés López collaborates with scholars based in Spain, Palestinian Territory and United States. Andrés López's co-authors include Eva González‐Barca, José Bruno Montoro Ronsano, Teresa Vallespı́, Albert Oriol, Armando López‐Guillermo, Josep‐María Ribera, Eugènia Abella, Mireia Morgades, Pilar Miralles and Santiago Gardella and has published in prestigious journals such as Blood, Cancer and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Andrés López

27 papers receiving 396 citations

Peers

Countries citing papers authored by Andrés López

Since Specialization

Citations

This map shows the geographic impact of Andrés López's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrés López with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrés López more than expected).

Fields of papers citing papers by Andrés López

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrés López. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrés López. The network helps show where Andrés López may publish in the future.

Co-authorship network of co-authors of Andrés López

This figure shows the co-authorship network connecting the top 25 collaborators of Andrés López. A scholar is included among the top collaborators of Andrés López based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrés López. Andrés López is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Effect of First Metatarsal Shortening and Sagittal Displacement on Forefoot Pressure in Minimally Invasive Hallux Valgus Correction 2024 ·Foot & Ankle Specialist ·Andrés López, (unknown), (unknown), (unknown), (unknown), J. Benjamin Jackson, Tyler Gonzalez, (unknown)	2
2	Functional assessment of a whey protein hydrolysate: In vivo responses in lipid regulation, oxidant defense, and neural protection in Caenorhabditis elegans 2024 ·International Dairy Journal ·(unknown), (unknown), Andrés López, Núria González, (unknown), (unknown), Silvia Llopis, (unknown), Bernadette Klotz	2
3	Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients 2020 ·Annals of Hematology ·(unknown), Eva González‐Barca, Francisco Capote, José Gómez‐Codina, Carlos Panizo, Antonio Salar, Juan‐Manuel Sancho, Andrés López, Javier Briones, Andrés Muñoz, Maite Encuentra, Santiago Mercadal, Eva Domingo‐Doménech, Alberto Fernández de Sevilla	8
4	Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial 2019 ·Cancer Medicine ·Francisco‐Javier Peñalver, (unknown), (unknown), Pilar Giraldo, Alejandro Martı́n, Carlos Montalbán, Juan‐Manuel Sancho, (unknown), María José Terol, F. Capote, Antonio Gutiérrez, (unknown), Andrés López, Antonio Salar, Gil Rodríguez‐Caravaca, Miguel Canales, (unknown), (unknown)	4
5	Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series 2018 ·Annals of Hematology ·(unknown), Sabela Bobillo, Pau Abrisqueta, Blanca Sánchez‐González, Eva Giné, (unknown), Miguel Alcoceba, Eva González‐Barca, Sonia González de Villambrosía, Juan‐Manuel Sancho, (unknown), Leyre Bento, José Bruno Montoro Ronsano, (unknown), Andrés López, (unknown)	6
6	Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group 2013 ·Annals of Hematology ·Dolores Caballero, Elı́as Campo, Armando López‐Guillermo, Alejandro Martı́n, (unknown), Eva Giné, Andrés López, Eva González‐Barca, Miguel Canales, Marcos González, Alberto Órfão	12
7	Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study 2013 ·European Journal of Cancer Care ·(unknown), F. Carabantes, Sònia Pernas, Blanca Cantos, Andrés López, Pilar Rioja Torres, (unknown), Dolores Caballero, (unknown), Antonio Salar, (unknown)	18
8	Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma 2012 ·Blood ·Mercedes Gironella, Andrés López, (unknown), Pau Abrisqueta, (unknown), Francesc Bosch	4
9	Rituximab Plus Gemcitabine and Oxaliplatin as Salvage Therapy In Patients with Relapsed/Refractory Mantle-Cell Lymphoma. 2010 ·Blood ·Mercedes Gironella, Andrés López, Pau Abrisqueta, (unknown), Noelia Purroy, Francesc Bosch	3
10	Predictive Value for Event-Free Survival of Interim 18F-FDG-PET In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim as First-Line Treatment: An Open-Label Clinical Trial In Spain. 2010 ·Blood ·Eva González‐Barca, Miguel Canales, María Vidal, Albert Oriol, Antonio Salar, Joan Bargay, (unknown), J. Coya, José Francisco Tomás, Andrés López, José Javier Sánchez, (unknown), (unknown), Secundino Ferrer, Dolores Caballero	2
11	Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma 2007 ·Leukemia & lymphoma ·José Rodríguez, Antonio Gutiérrez, (unknown), (unknown), Isabel Blancas, Jesús Alarcón, (unknown), Silvia Fernández de Mattos, (unknown), (unknown), Andrés López	35
12	Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus‐associated diffuse large B‐cell lymphoma: results of a phase II trial 2007 ·British Journal of Haematology ·Josep‐María Ribera, Albert Oriol, Mireia Morgades, Eva González‐Barca, Pilar Miralles, Armando López‐Guillermo, Santiago Gardella, Andrés López, Eugènia Abella, (unknown), (unknown)	72
13	Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center 2002 ·Leukemia Research ·(unknown), Javier Bueno, (unknown), Andrés López, Teresa Vallespı́, (unknown)	43
14	Five novel single nucleotide polymorphisms of the RB1 gene (g.5625T>C, g.70169T>G, g.76875A>T, g.78026delA, and g.150072T>C) in retinoblastoma patients 2001 ·Human Mutation ·Javier Alonso, (unknown), Andrés López, Marta Mendiola, Purificación García‐Miguel, (unknown), (unknown), M. Vendrell, Aurora Navajas, Ángel Pestaña	4
15	Usefulness and Reproducibility of Cytomorphologic Evaluations to Differentiate Myeloma From Monoclonal Gammopathies of Unknown Significance 2001 ·American Journal of Clinical Pathology ·Fuensanta Millá, Albert Oriol, José‐Luis González de Aguilar, Ana Aventín, R Ayats, Esther Alonso, Alícia Domingo, Evarist Feliú, Lourdes Florensa, Andrés López, (unknown), Marı́a Rozman, Carmen Sánchez, Teresa Vallespı́, S Woessner	13
16	La imagen de la semana 2001 ·Medicina Clínica ·César Jiménez, Andrés López, (unknown), N Tallada	0
17	Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas. 2001 ·PubMed ·Carlos Palacio, (unknown), (unknown), C Ruiz-Marcellán, Carmen Sánchez, (unknown), Andrés López	27
18	Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia 1996 ·Antimicrobial Agents and Chemotherapy ·(unknown), Rosa María López, José Bruno Montoro Ronsano, (unknown), L. Pou, (unknown), Andrés López, Bernat Planas Pascual	46
19	Administration of Lipid-Emulsion Versus Conventional Amphotericin B in Patients with Neutropenia 1995 ·Annals of Pharmacotherapy ·(unknown), (unknown), José Bruno Montoro Ronsano, Juan Oliveras, (unknown), (unknown), Andrés López	19
20	Survival after intestinal mucormycosis in acute myelogenous leukemia 1986 ·Cancer ·Rafael Parra, (unknown), Antonio Julià, Andrés López, (unknown), Elena Allende	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact